Skip to main content
All lobbying filings

STUDENTS FOR SENSIBLE DRUG POLICY

Lobbying for STUDENTS FOR SENSIBLE DRUG POLICY

 Filing Q1 report
Reporting period
1st Quarter 2026
Jan 1 - Mar 31 · Posted Apr 12, 2026
Money reported
None
Registrations and no-activity reports carry no figure.
Client based in
District of Columbia

Official filing document

 Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

 Bills named in this filing 8
 Lobbying activity 2

STATES 2.0 Act (HR 2934): Issues related state cannabis laws and provisions to enable interstate commerce. PREPARE Act (HR 2935): Issues related to the establishment of a federal commission to design a pathway for full federal cannabis regulation. Evidence-Based Drug Policy Act (HR 3082): Issues related to the authorization of federal agencies to study cannabis legalization and stops requiring the Drug Czar to oppose reform efforts. MORE Act (HR 5068): Issues related to the removal of cannabis from the Controlled Substances Act, expunging certain past convictions, and reinvesting in communities disproportionately harmed by prohibition. The End Needless Distribution of 7-OH Act (H.R. 8000): Issues related to restricting the distribution of synthetic 7-OH products by treating them as a federally controlled substance with no accepted medical use.

Veterans Cannabis Use for Safe Healing Act (HR 966): Issues related to the denial of VA benefits to veterans enrolled in state-approved medical cannabis programs and requiring VA providers to discuss and document cannabis use and adjust treatment. Veterans Equal Access Act (HR 1384): Issues related to the authorization of the VA to offer veterans recommendations and opinions regarding participation in their state's respective cannabis programs. Innovative Therapies Centers of Excellence Act of 2025 (HR 2623): Issues related to the designation of at least five VA medical facilities as Innovative Therapies Centers of Excellence.

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.

Report a problem